Krish Patel

381 posts

Krish Patel banner
Krish Patel

Krish Patel

@KrishPatelMD

Director #lymphoma #Research @SarahCannonDocs @SCRIOncology #Duke alum x4. Foodie. Dad of 2. Husband. Tweets my own, not medical advice. #cll #lymsm

Nashville, TN Katılım Kasım 2013
322 Takip Edilen946 Takipçiler
Krish Patel
Krish Patel@KrishPatelMD·
Excited to join a stellar crew of faculty in Nashville for this exciting meeting!
Nashville Hematology Conference@NashvilleHeme

Excited to highlight faculty member Dr. @KrishPatelMD, Director of Lymphoma Research at Sarah Cannon Research Institute and expert medical oncologist at SCRI Oncology Partners in Nashville! With his focus on novel therapeutics, cellular therapies, and clinical trials for lymphomas and CLL, he's delivering game-changing insights to #NashvilleHeme26. FREE registration is still open for this 2-day CE-accredited conference, Feb 26-28, 2026. Secure your spot with code FREECME and join over 60 top experts: na2.hubs.ly/H03qYDn0 #Hematology #CME

English
0
0
7
587
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
This is possibly the most controversial finding in immuno-oncology. The effect size is hard to believe. Though RCTs are hard NOT to believe. We need a coordinated effort between academia & pharma to look back at prior RCTs to investigate this. For the safety of our patients.
Eric Topol@EricTopol

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system nature.com/articles/s4159…

English
32
83
748
112.4K
Eric Topol
Eric Topol@EricTopol·
The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system nature.com/articles/s4159…
Eric Topol tweet media
English
49
336
1.4K
541.3K
Krish Patel retweetledi
Sarah Cannon Docs
Sarah Cannon Docs@SarahCannonDocs·
We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI. His legacy: 850+ first-in-human trials, countless lives impacted. 💙 Welcome new leaders and read the full update: scri.com/news/scri-anno…
English
1
1
16
7.1K
Krish Patel retweetledi
PeerView
PeerView@PeerView·
What's New in #DLBCL care? Learn how BTK inhibitors, antibody-based therapies, and bispecifics are changing the game for frontline & relapsed/refractory disease. Join this expert-led #MedEd program featuring Krish Patel, MD (@KrishPatelMD). #PeerView 🔗 bit.ly/4jfWkG4
English
0
3
6
214
Krish Patel retweetledi
Mazyar Shadman, MD MPH
Mazyar Shadman, MD MPH@mshadman·
This Friday and Saturday in Seattle! Take a look at the agenda and the list of speakers! #group-tabs-node-course-default2" target="_blank" rel="nofollow noopener">education.binaytara.org/content/2025-s… Looking forward to seeing you all! @binaytara @fredhutch #SeattleCT25
Binaytara@binaytara

3 DAYS TO GO! Join @mshadman and @KrishPatelMD at #SeattleCT25! Connect with leading oncologists from @fredhutch @uwmedicine @SarahCannonDocs @NebraskaMed @MDAndersonNews @ProvSwedish. Register TODAY: buff.ly/z3cKHdl #MedX #MedTwitter #leusm #lymsm #CLLsm #hemepath #ALL

English
0
7
29
4K
Krish Patel
Krish Patel@KrishPatelMD·
@Eddie_Cliff @HemSandoval @graham74GC In US, there is substantial dropout (death from progression) from 2L chemo to 3L+Cart due to dz kinetics, time (consult, insurance auth, aph, etc). Adjustment allows us to see a potential OS benefit to giving CAR 2L (as shown in ZUMA7) as some pts may not reliably have access 3L+
English
1
0
2
108
Krish Patel
Krish Patel@KrishPatelMD·
@Eddie_Cliff @HemSandoval @graham74GC Imo this adjustment is fair & impt. Recall all pts were leukapheresed upfront regardless of arm assigned. So crossover in this study is primed for rapid delivery of 3L cart in soc arm at progression, not quite what happens in real world. Adjustment informs on 2L vs 3L sequencing.
English
1
0
1
182
Graham Collins
Graham Collins@graham74GC·
Kamdar et al; 3y FU of TRANSFORM study - Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL. Impressive PFS & EFS benefit Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm. No new tox signal. ascopubs.org/doi/10.1200/JC…
Graham Collins tweet media
English
3
18
53
5.2K
Krish Patel retweetledi
Kai Rejeski
Kai Rejeski@KRejeski·
Can off-the-shelf iPSC-derived NK cells change the game for B-cell lymphoma? @tix_tobi and I had the opportunity to reflect on an early-phase study by Strati et al, published in @TheLancetHaem , studying FT516—a non-CAR-bearing, iPSC-derived NK-cell Tx. thelancet.com/journals/lanha…
Munich, Germany 🇩🇪 English
1
5
12
1.5K
Krish Patel retweetledi
Lymphoma Hub
Lymphoma Hub@lymphomahub·
CONGRESS | #18ICML | PRESENTATION Krish Patel @KrishPatelMD, Sarah Cannon Research Institute, presents global phase Ib results of JNJ-90014496, a CD19/CD20 bispecific CAR T-cell therapy, in R/R LBCL (N = 48). At the RP2D (75M cells), ORR and CRR were 95% and 80%, respectively, with no G3/4 CRS and 1 ICANS. Safety was manageable and consistent with the prior China study. Follow our live feed for more updates: loom.ly/Pc0ysis #Lymphoma #lymsm #MedicalCongress
Lymphoma Hub tweet mediaLymphoma Hub tweet mediaLymphoma Hub tweet mediaLymphoma Hub tweet media
English
0
4
5
793
Krish Patel retweetledi
Binaytara
Binaytara@binaytara·
Join the CME/ACPE-accredited 2025 Seattle Cellular Therapy Summit, where leading experts deliver insights on CAR T therapies, lymphoma management, and breakthrough strategies for hematologic malignancies. Register NOW: buff.ly/eJkilhc
English
0
1
2
5.7K

Keşfet

@HemSandoval @PTarantinoMD @DrPaulyDeSantis @RShouval @EricTopol @niravshahmd @MeredithPelster @SarahCannonDocs